To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia?

Current Opinion in Urology

Volumn 16, Issue 1, 2006, Pages 1-4

  Mishra, Vibhash ^a   Emberton, Mark ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Randomized controlled trials; Real life practice studies

Indexed keywords

ALFUZOSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CYSTOSCOPY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INTERMETHOD COMPARISON; MEDICAL PRACTICE; MEDICAL RECORD; ORTHOSTATIC HYPOTENSION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; URETHRA DISEASE; URINARY TRACT DISEASE; URINE RETENTION;

HUMANS; INCIDENCE; MALE; PREVALENCE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; URINARY RETENTION;

EID: 29944440499     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000193369.99446.ac     Document Type: Review

References (23)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132:474-479.
2. Verhamme KMC, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - The Triumph Project. Eur Urol 2002; 42:323-328.
3. Verhamme KMC, Dieleman JP, Bleumink GS, et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: The Triumph Project. Eur Urol 2003; 44:539-545.
4. U.S. Bureau of the Census, International Data Base. (August 2000): http://www.census.gov.
5. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155:595-600.
6. Lee AJ, Russell AW, Garraway WM, Prescot RJ. Three-year follow up of a community based cohort of men with untreated benign prostatic hyperplasia. Eur Urol 1996; 30:11-17.
7. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999; 54:670-678.
8. Flanigan RC, Reda DJ, Wasson JH, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs Cooperative study. J Urol 1998; 160:12-17.
9. Rosenberg W, Donald A. Evidence-based medicine: An approach to clinical problem solving. BMJ 1995; 310:1122-1126.
10. Black N. Experimental and observational methods of evaluation. BMJ 1994; 309:540.
11. Cross design synthesis: a new strategy for studying medical outcomes? Lancet 1992; 340:944-946.
12. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312:1215-1218.
13. Roberts RO, Rhodes T, Girman CJ, et al. The decision to seek care: factors associated with the propensity to seek care in a community-based cohort of men. Arch Fam Med 1997; 6:218.
14. Michel MC, Mehlburger L, Bressel H-U, et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: Does co-morbidity alter tolerability? J Urol 1998; 160:784-791.
15. Verhamme KMC, Dieleman JP, van Wijk MAM, et al. Low incidence of acute urinary retention in the general male population: The Triumph Project. Eur Urol 2005; 47:494-498. This paper describes the incidence of AUR in the general male population and in those with newly diagnosed BPH and gives a perspective to the strategies to prevent AUR.
16. Souverein PC, van Riemsdijk MM, de la Rosette JJMCH, et al. Treatment of benign prostatic hyperplasia and occurrence of prostatic surgery and acute urinary retention: A population-based cohort study in the Netherlands. Eur Urol 2005; 47:505-510. An important study that confirms the findings of the PLESS study in a RLP situation.
17. Clifford GM, Logie J, Farmer RDT. How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol 2000; 38(suppl 1):40-47.
18. Emberton M, Elhilali M, Matzkin H, et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 2005; 66:316-322. The first study to show that dynamic variables have much more predictive value in BPH progression than baseline characteristics.
19. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398.
20. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338:557-563.
21. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2000; 37:306-313.
22. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A randomized, placebo-controlled trial. Urology 2001; 58:953-959.
23. Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335:533-539.